TILT preparations during the corona pandemic
The ongoing pandemic affects TILT less than some other companies. This is because we don’t have regular sales. Instead, our operations are based on long term research and development. It is clear corona might cause unexpected delays in the upcoming year, but likely these can be compensated for afterwards. The management team of the company is relatively small and few are members of any risk group. Most of our work can be performed from home offices. Laboratory work is currently allowed to continue in Finland. Production of our drug has been completed. Most of our costs are outsourced, giving us flexibility should the global situation worsen. We will stay vigilant and modify our plans as needed.